Monitor for issuance of the Japanese patent after payment of the issuance fee, and for additional patent grants in other geographic regions. No near-term revenue catalyst, but IP strength supports long-term commercial positioning in Asia.
Price Chart
Executive Summary
bioAffinity Technologies announced that the Japan Patent Office issued a Notice of Allowance for a patent covering its CyPath Lung test for early-stage lung cancer. This is the first Japanese patent for the AI-built algorithm and the fifth in Asia, expanding the company's IP portfolio to 22 awarded patents. The event is a positive IP milestone but does not change near-term revenue or clinical adoption trajectory.
Key Facts
- Japan Patent Office issued a Notice of Allowance for a patent on the method of predicting lung cancer using CyPath Lung
- Japanese patent will be the first awarded in Japan for CyPath Lung driven by an AI-built algorithm
- Fifth patent protecting CyPath Lung awarded in Asia, including China and Hong Kong
- Company's total IP portfolio includes 22 awarded U.S. and foreign patents and 36 pending patent applications
- CyPath Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services
Financial Impact
No financial figures disclosed; IP expansion supports potential future licensing or market exclusivity in Japan and Asia
Risk Factors
- Patent issuance is not yet final — requires payment of issuance fee
- CyPath Lung is currently marketed only as an LDT, limiting scalability without FDA clearance
- No disclosed revenue or adoption metrics from existing markets
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-046266 |
| Exhibit: ex99-1.htm | 0001493152-26-046266 |
| Document: 0001493152-26-046266-index-headers.html | 0001493152-26-046266 |
| Document: 0001493152-26-046266-index.html | 0001493152-26-046266 |
| Document: 0001493152-26-046266.txt | 0001493152-26-046266 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | DEF 14A | $2.81 | awaiting T+1 | — | $3.00 (+6.76%) |
Oct 15, 2026 12d ago | 8-K | $3.96 $3.73 | ▼ −5.81% | ▼ −4.70% | $3.00 (−24.24%) |
Oct 13, 2026 14d ago | 8-K | $3.63 $3.56 | ▼ −1.79% | ▼ −0.71% | $3.00 (−17.24%) |
Oct 9, 2026 17d ago | 8-K | $3.90 $3.63 | ▲ +7.05% | ▲ +7.04% | $3.00 (+23.08%) |
Oct 9, 2026 17d ago | 424B5 | $4.73 $3.90 | ▲ +17.46% | ▲ +17.40% | $3.00 (+36.51%) |
Oct 9, 2026 17d ago | 424B5 | $4.73 $3.90 | ▼ −17.46% | ▼ −17.40% | $3.00 (−36.51%) |
Oct 8, 2026 19d ago | 8-K | $5.64 $4.73 | ▼ −16.22% | ▼ −16.82% | $3.00 (−46.81%) |
Oct 6, 2026 21d ago | 8-K | $6.06 $6.16 | ▲ +1.65% | ▲ +1.89% | $3.00 (−50.50%) |
Sep 30, 2026 27d ago | 8-K | $6.56 $6.15 | ▼ −6.33% | ▼ −6.50% | $3.00 (−54.27%) |
Sep 22, 2026 5w ago | 8-K | $8.56 $7.94 | ▼ −7.19% | ▼ −6.47% | $3.00 (−64.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers